Savino Bruno, MD; Mauro Borzio, MD; Pier Maria Battezzati, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Bruno S, Borzio M, Battezzati PM. Interferon-α in Chronic Hepatitis C. Ann Intern Med. 1998;128:956. doi: 10.7326/0003-4819-128-11-199806010-00020
Download citation file:
Published: Ann Intern Med. 1998;128(11):956.
TO THE EDITOR:
Marcellin and colleagues' study  suggests that patients with chronic hepatitis C showing sustained response to interferon-α have a low risk for development of hepatocellular carcinoma. We are following a cohort of 23 long-term responders (5 with cirrhosis) who received interferon-α2a in a randomized clinical trial  and were observed for a mean (±SD) of 77 ± 20 months (range, 50 to 114 months) after discontinuation of treatment. Sustained response was defined as persistently normal alanine aminotransferase levels at monthly determinations during the first 12 months after discontinuation of interferon-α2a and every 3 months afterward. Hepatitis C virus (HCV) RNA was quantitatively and qualitatively measured by nested polymerase chain reaction (as described by Manzin and colleagues ) at the end of treatment and at 6-month intervals thereafter. Patients with cirrhosis underwent abdominal ultrasonography twice yearly. For all patients, liver histologic findings were available at baseline and 1 year after discontinuation of interferon-α2a therapy.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only